5 news items
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
BPTH
24 May 24
." Details for the poster presentation are as follows: Title: Interim Safety and Efficacy of BP1001
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
BPTH
23 May 24
: Title: Interim Safety and Efficacy of BP1001 in a Phase II Acute Myeloid Leukemia StudyDate
Bio-Path Holdings Reports First Quarter 2024 Financial Results
BPTH
15 May 24
of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BPTH
18 Apr 24
that its benign safety profile should enable effective BP1002 combination therapy with approved agents, such as decitabine. The Phase 1/1b clinical
Bio-Path Holdings Provides 2024 Clinical and Operational Update
BPTH
2 Apr 24
of prexigebersen and decitabine. Based on positive interim data for safety and efficacy, the Company plans to pursue FDA Fast Track designation
- Prev
- 1
- Next